Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors.
Overview
- Department of Neurological Surgery, Northwestern University, Chicago, IL, USA
- Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
- Department of Pathology, Northwestern University, Chicago, IL, USA
- Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Chicago, IL, USA
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Department of Laboratory Medicine & Pathology, Mayo Clinic Florida, Jacksonville, FL, USA
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
- Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Abstract
Bispecific T cell engagers (BTEs) induce MHC‐independent cytotoxicity by bridging T cells to tumor cells via binding a T cell–activating receptor and a tumor‐associated antigen. BTEs have proven effective in hematologic malignancies and some solid tumors, yet their potential in glioblastoma (GBM) is largely unexplored. We developed a fully humanized BTE (hBTE) targeting interleukin‐13 receptor alpha 2 (IL13RA2), a tumor‐associated antigen widely expressed in GBM and associated with poor prognosis. In vitro, hBTE activated T cells and induced antigen‐dependent cytokine release and cytotoxicity against IL13RA2‐positive GBM cells. In vivo, hBTE showed robust target‐specific activity and markedly prolonged survival in primary and recurrent GBM xenograft models, without detectable off‐target local or systemic toxicity. Beyond GBM, hBTE also exhibited antitumor activity in IL13RA2‐expressing solid tumors, demonstrating selective tumor accumulation and therapeutic efficacy in models of breast cancer brain metastases and extracranial lung cancer. This work highlights the therapeutic potential of BTEs in IL13RA2‐expressing tumors and establishes a strong preclinical rationale for advancing hBTE therapy toward clinical translation in GBM and other tumors.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Data links
- ncbi.nlm.nih.gov/
geo/ , NCBI; found in “Analysis of Publicly Available RNA Sequencing…”query
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 30 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 17 authors, 7 keywords, 13 MeSH terms, 5 funders, 76 references, 3 RRIDs.
Cite
This paper
Duffy, J. T., Martin‐Regalado, A., Haupt, B. E., Pogue, J. R., Thakur, A., Cota, M. F., Zannikou, M., Misener, S., Krymskaya, V. P., McCortney, K., Miska, J., Horbinski, C., Simberg, D., Lesniak, M. S., James, C. D., Stupp, R., & Balyasnikova, I. V. (2026). Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(35), e22391. https://
BibTeX
@article{duffy2026fully,
author = {Duffy, Joseph T and Martin‐Regalado, Angela and Haupt, Benedikt E and Pogue, Jacob R and Thakur, Aditi and Cota, Manuel Fierro and Zannikou, Markella and Misener, Sol and Krymskaya, Vera P and McCortney, Kathleen and Miska, Jason and Horbinski, Craig and Simberg, Dmitri and Lesniak, Maciej S and James, Charles D and Stupp, Roger and Balyasnikova, Irina V},
title = {{Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors}},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
year = {2026},
month = apr,
volume = {13},
number = {35},
pages = {e22391},
publisher = {Wiley},
issn = {2198-3844},
doi = {10.1002/
url = {https://
pmid = {42057694},
pmcid = {PMC13292153}
}
RIS
TY - JOUR
AU - Duffy, Joseph T
AU - Martin‐Regalado, Angela
AU - Haupt, Benedikt E
AU - Pogue, Jacob R
AU - Thakur, Aditi
AU - Cota, Manuel Fierro
AU - Zannikou, Markella
AU - Misener, Sol
AU - Krymskaya, Vera P
AU - McCortney, Kathleen
AU - Miska, Jason
AU - Horbinski, Craig
AU - Simberg, Dmitri
AU - Lesniak, Maciej S
AU - James, Charles D
AU - Stupp, Roger
AU - Balyasnikova, Irina V
TI - Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors
T2 - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
J2 - Adv Sci (Weinh)
PY - 2026
DA - 2026/
VL - 13
IS - 35
SP - e22391
SN - 2198-3844
PB - Wiley
DO - 10.1002/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1002/
"type": "article-journal",
"title": "Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors",
"container-title": "Advanced science (Weinheim, Baden-Wurttemberg, Germany)",
"author": [
{
"family": "Duffy",
"given": "Joseph T"
},
{
"family": "Martin‐Regalado",
"given": "Angela"
},
{
"family": "Haupt",
"given": "Benedikt E"
},
{
"family": "Pogue",
"given": "Jacob R"
},
{
"family": "Thakur",
"given": "Aditi"
},
{
"family": "Cota",
"given": "Manuel Fierro"
},
{
"family": "Zannikou",
"given": "Markella"
},
{
"family": "Misener",
"given": "Sol"
},
{
"family": "Krymskaya",
"given": "Vera P"
},
{
"family": "McCortney",
"given": "Kathleen"
},
{
"family": "Miska",
"given": "Jason"
},
{
"family": "Horbinski",
"given": "Craig"
},
{
"family": "Simberg",
"given": "Dmitri"
},
{
"family": "Lesniak",
"given": "Maciej S"
},
{
"family": "James",
"given": "Charles D"
},
{
"family": "Stupp",
"given": "Roger"
},
{
"family": "Balyasnikova",
"given": "Irina V"
}
],
"container-title-short":
"volume": "13",
"issue": "35",
"page": "e22391",
"DOI": "10.1002/
"PMID": "42057694",
"PMCID": "PMC13292153",
"ISSN": "2198-3844",
"publisher": "Wiley",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
30
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.neo.2025.101271
- THOC1 complexes with SIN3A to regulate R-loops and promote glioblastoma progression.Journal: Neoplasia (New York, N.Y.)In common: other condition, mouse, cellular / molecular, 2 references, author Joseph T Duffy
- [2] doi:10.1073/pnas.2521256123
- Microglial fructose metabolism is essential for glioblastoma growth.Journal: Proceedings of the National Academy of Sciences of the United States of AmericaIn common: other condition, mouse, cellular / molecular, 1 reference, author Irina V Balyasnikova
- [3] doi:10.1007/s10585-025-10362-1
- Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF-κB signaling.Journal: Clinical & experimental metastasisIn common: other condition, mouse, cellular / molecular, 3 references
- [4] doi:10.1038/s41540-025-00642-7 [code]
- Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment.Journal: NPJ systems biology and applicationsIn common: other condition, 4 references
- [5] doi:10.1038/s41467-023-37328-9
- STING agonist-loaded, CD47/
PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Journal: Nature communicationsIn common: other condition, mouse, cellular / molecular, 3 references - [6] doi:10.1016/j.cell.2026.05.026 [code]
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.Journal: CellIn common: other condition, 4 references
- [7] doi:10.1038/s41598-024-60031-8
- RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma.Journal: Scientific reportsIn common: other condition, mouse, cellular / molecular, 3 references
- [8] doi:10.1038/s41591-024-03152-x
- Cranioencephalic functional lymphoid units in glioblastoma.Journal: Nature medicineIn common: other condition, 3 references
- [9] doi:10.1038/s41419-025-07363-z
- Overexpression of miR-124 enhances the therapeutic benefit of TMZ treatment in the orthotopic GBM mice model by inhibition of DNA damage repair.Journal: Cell death & diseaseIn common: other condition, mouse, 3 references
- [10] doi:10.1158/2767-9764.crc-25-0579 [code]
- Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses.Journal: Cancer research communicationsIn common: other condition, mouse, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
